RxDoctor Payments Data

Marissa Marti-Smith

Gerontology · Dallas, TXNPI 1992273833

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $17,250 of the $26,712 with a category attached, or 64.6%. Stemline Therapeutics Inc. accounts for 92.4% of it on its own, with 13 other manufacturers making up the rest. Among gerontology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$26,712in general payments, 2019–2025

Across 153 payments — averaging $174.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stemline Therapeutics Inc.$25K
  • AstraZeneca$656
  • Daiichi Sankyo Inc.$385
  • Seagen Inc.$325
  • Gilead$172
  • Novartis$145
  • plus $336 from 8 others

What the payments were for

  • Consulting fees$3251%
  • Speaking & faculty fees$17,25065%
  • Travel & lodging$5,42520%
  • Food & beverage$3,68814%
  • Education$250%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,712 in reported general payments places this provider in the 95th percentile of 653 gerontology providers in Texas.

See all gerontology providers in Texas

Medicare billing

Part B allowed, 2024
$68,345
Medicare patients
240
Services billed
2,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Anastrozole56$1,400
Duloxetine Hcl16$337
Letrozole15$310
Zolpidem Tartrate19$114
Trazodone Hcl20$32

Paid to pharmacies, not to this prescriber.

Other gerontology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →